Researchers at the Christian Albrechts University of Kiel and the MRC London Institute of Medical Science have developed a way to screen four-way interactions between genetically simple hosts, their microbiome, nutrients and drugs.
LONDON – Themis Bioscience GmbH has landed an exclusive licensing deal with Merck & Co. Inc., which simultaneously validates its measles virus-based vaccines platform and provides the means to extend the technology to new indications.
Researchers at Stony Brook University have found a way to keep insulin-degrading enzyme (IDE) from deactivating insulin without affecting its role in degrading glucagon.
LONDON – Themis Bioscience GmbH has announced positive phase II results for its vaccine against Chikungunya virus, as it moves to complete an IPO later this week to raise up to €55 million (US$62.6 million) to fund the launch of a pivotal phase III trial.
Drug prices were part of the conversation Wednesday as delegates to the 71st World Health Assembly asked the World Health Organization (WHO) to elaborate on a five-year roadmap to address the global shortage of, and access to, medicines and vaccines that's to be presented at next year's assembly.
DUBLIN – The Coalition for Epidemic Preparedness Innovations (CEPI), an international public-private partnership raising $1 billion to incentivize the development of vaccines for neglected infectious diseases, has made its first big bet – a contract, worth up to $37.5 million, with Themis Bioscience GmbH to develop vaccines against Lassa virus and Middle East respiratory syndrome-related coronavirus (MERS-CoV).